Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, 600 Yishan Rd, Shanghai, 200233, China.
Department of Endocrinology and Metabolism, Ningbo First Hospital, 59 Liuting Street, Ningbo, 315000, Zhejiang Province, China.
Trials. 2023 Jun 19;24(1):411. doi: 10.1186/s13063-023-07427-5.
Low-carbohydrate diet (LCD) is an emerging therapy for type 2 diabetes mellitus (T2DM). Although its effect on glucose control has been confirmed in previous clinical trials, most of those studies have focused on comparing calorie-restricted LCD to iso-caloric low-fat diets. In this study, we aim to compare the effects of LCD and canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with T2DM.
This is a multicenter, randomized controlled trial. We will recruit 120 patients with poor-controlled T2DM. Participants will be randomly divided into canagliflozin and LCD groups in a 1:1 ratio. The primary outcome is the change in hemoglobin A1C levels after the 3-month intervention. The secondary outcomes are the time in range and cost of antihyperglycemic agents. Exploratory outcomes include physical examination, body composition, glucose variability, appetite, glycolipid metabolism, liver lipid content, and urine glucose threshold.
No previous study has compared an LCD with antihyperglycemic agents. In LoCaT, participants' metabolism will be assessed from multiple perspectives. It is believed that the finding obtained from this trial will optimize the treatments for patients with T2DM.
Chinese Clinical Trial Registry ChiCTR1900027592. Registered on November 20, 2019.
低碳水化合物饮食（LCD）是治疗 2 型糖尿病（T2DM）的一种新兴疗法。尽管之前的临床试验已经证实了它对血糖控制的影响，但这些研究大多集中在比较热量限制的 LCD 与等热量低脂饮食。在这项研究中，我们旨在比较 LCD 和卡格列净（一种钠-葡萄糖协同转运蛋白 2 抑制剂）在 T2DM 患者中的疗效。
这是一项多中心、随机对照试验。我们将招募 120 名血糖控制不佳的 T2DM 患者。参与者将以 1:1 的比例随机分为卡格列净组和 LCD 组。主要结局是干预 3 个月后糖化血红蛋白水平的变化。次要结局是血糖达标时间和抗高血糖药物的成本。探索性结局包括体格检查、身体成分、血糖变异性、食欲、糖脂代谢、肝脂质含量和尿糖阈值。
以前没有研究比较过 LCD 和抗高血糖药物。在 LoCaT 中，将从多个角度评估参与者的代谢情况。相信从这项试验中获得的发现将优化 T2DM 患者的治疗方案。
中国临床试验注册中心 ChiCTR1900027592。于 2019 年 11 月 20 日注册。
